Lyka Labs Limited Schedules Board Meeting on May 25, 2026 to Approve Q4 and FY26 Financial Results

Lyka Labs Limited has notified the stock exchanges of an upcoming Board of Directors meeting, scheduled for Monday, May 25, 2026. The intimation was issued pursuant to Regulation 29(1)(a) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and communicated to both BSE Limited and the National Stock Exchange of India Limited on May 12, 2026.

Board Meeting Agenda

The board meeting has been convened to consider and approve key financial disclosures. The following items are on the agenda:

Audited Standalone and Consolidated financial results of the Company for the quarter and financial year ended March 31, 2026
Any other businesses

Meeting Details at a Glance

The key details of the scheduled board meeting are summarised below:

Parameter:	Details
Meeting Date:	Monday, May 25, 2026
Purpose:	Approval of Q4 and FY26 Audited Financial Results
Results Type:	Standalone and Consolidated
Period Covered:	Quarter and financial year ended March 31, 2026
Regulatory Reference:	Regulation 29(1)(a) of SEBI (LODR) Regulations, 2015
Intimation Date:	May 12, 2026
Signatory:	Shailendra Kumar Agrawal, Company Secretary and Compliance Officer
Place:	Mumbai

Regulatory Compliance

The intimation has been filed in compliance with SEBI's listing obligations framework, which mandates advance disclosure of board meetings where financial results are to be considered. Lyka Labs has also made this information available on its official website at www.lykalabs.com , in line with applicable disclosure requirements.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-4.58%	-10.06%	+4.02%	-33.13%	-47.32%	+18.07%

Lyka Labs Limited has successfully completed its amalgamation with Lyka Exports Limited, with the scheme becoming effective from April 8, 2026. The company informed the stock exchanges about this significant corporate development through a regulatory filing under SEBI Listing Regulations.

NCLT Approval and Implementation Timeline

The scheme of amalgamation received judicial approval from the National Company Law Tribunal, Ahmedabad Bench on March 16, 2026. The company received the certified true copy of the NCLT order on March 24, 2026. Subsequently, both the transferor company (Lyka Exports Limited) and the transferee company (Lyka Labs Limited) filed the certified copy with the Registrar of Companies, Ahmedabad on April 8, 2026.

Parameter:	Details
NCLT Order Date:	March 16, 2026
Certified Copy Received:	March 24, 2026
ROC Filing Date:	April 8, 2026
Scheme Effective Date:	April 8, 2026
Appointed Date:	April 1, 2022

Authorized Share Capital Enhancement

Following the effectiveness of the amalgamation scheme, Lyka Labs Limited's authorized share capital has been automatically increased by the aggregate authorized share capital of Lyka Exports Limited. The company's Memorandum of Association has been amended to reflect this change in Clause V.

Share Type:	Number of Shares	Face Value	Amount
Equity Shares:	5,70,00,000	Rs.10.00 each	Rs.57,00,00,000
Redeemable Preference Shares:	2,00,000	Rs.100.00 each	Rs.2,00,00,000
Total Authorized Capital:			Rs.59,00,00,000

Corporate Structure Impact

The amalgamation involves Lyka Exports Limited as the transferor company merging with Lyka Labs Limited as the transferee company. This corporate restructuring affects both companies' shareholders and creditors as per the approved scheme. The appointed date of April 1, 2022, indicates the effective date from which the financial and operational integration is considered for accounting and legal purposes.

The completion of this amalgamation represents a significant milestone in Lyka Labs Limited's corporate evolution, consolidating operations and potentially creating synergies between the merged entities. The company has fulfilled all regulatory requirements and obtained necessary approvals to execute this corporate restructuring successfully.